Stuart Y Keller
Overview
Explore the profile of Stuart Y Keller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Decker R, Ernest 2nd C, Radtke D, Wang R, Araujo J, Keller S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Mar;
13(6):970-981.
PMID: 38532270
Baricitinib is approved for the treatment of rheumatoid arthritis (RA) in more than 70 countries, and juvenile idiopathic arthritis (JIA) in the European Union. Population pharmacokinetic (PK) models were developed...
2.
Wickremsinhe E, Decker R, Lee L, Lelle E, Carlton L, Keller S, et al.
Bioanalysis
. 2023 Jun;
15(11):621-636.
PMID: 37293791
Managing blood volumes in pediatric studies is challenging and should be minimized where possible. A sensitive liquid chromatography with tandem mass spectrometry (LC-MS/MS) method was validated and implemented across two...
3.
Ramanan A, Guly C, Keller S, Schlichting D, de Bono S, Liao R, et al.
Trials
. 2021 Oct;
22(1):689.
PMID: 34627340
Background: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and the most common systemic disorder associated with uveitis in childhood. Uveitis is more common in JIA patients...
4.
Effron M, Nair K, Molife C, Keller S, Page 2nd R, Simeone J, et al.
Am J Cardiovasc Drugs
. 2017 Dec;
18(2):129-141.
PMID: 29222628
Background: No direct comparisons of ticagrelor and prasugrel with 1-year clinical follow-up have been reported. Objectives: Our objective was to compare 1-year clinical outcomes among patients with acute coronary syndrome...